Abstract

Objective: To determine the prevalence and risk factors of anti-tuberculosis drug induced liver injury (AT-DILI) while assessing gender differences and documenting incidence trends.
Methodology: We utilized a questionnaire survey, collection of sputum samples for acid-fast bacilli testing and liver function tests (LFTs).
Results: Out 100 patients, 35 were males and 65 females. A total of 45 patients were tested positive for acid-fast bacilli (AFB) on smear. Most patients exhibited regular LFT results, signifying unremarkable hepatic function during TB therapy. However, among relapse and post-TB cases, abnormal LFT findings were often accompanied by jaundice.
Conclusion: Among relapse and post-TB cases, abnormal LFT findings were often accompanied by jaundice. Further research is needed to elucidate mechanisms behind this increased vulnerability to prevent AT-DILI in populations.

Key words: Anti-tuberculosis drug therapy, drug-induced liver injury, DILI, Abnormal Liver function, Jaundice.